English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, November 30, 2021
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
Friday, November 26, 2021
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health
Thursday, November 25, 2021
中国抗体受邀出席首届亚洲医疗健康高峰论坛
中國抗體受邀出席首屆亞洲醫療健康高峰論壇
Thursday, November 18, 2021
重磅!B细胞CD22单抗SM03治疗类风湿关节炎临床研究结果最新公布!
Friday, September 17, 2021
中国抗体、信诺维与云顶新耀宣布签署新一代BTK抑制剂SN1011肾病领域的全球开发及商业化的授权协议
中國抗體、信諾維與雲頂新耀宣佈簽署新一代BTK抑制劑SN1011腎病領域的全球開發及商業化的授權協議
Wednesday, April 8, 2020
中国抗体获2020年EULAR年会口述陈述资格 发表SM03研究成果
Friday, September 17, 2021
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases
Monday, January 18, 2021
中国抗体SN1011之I期临床试验完成首例健康受试者给药

Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575